Lipid profile in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective lipid profile from single center

Calapkulu, Murat; CANDER, SONER; ÖZ GÜL, ÖZEN; ERSOY, CANAN

doi:10.1016/j.dsx.2019.01.016

Lipid profile in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective lipid profile from single center

Atıf İçin Kopyala

Calapkulu M., CANDER S., ÖZ GÜL Ö., ERSOY C.

DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, cilt.13, sa.2, ss.1031-1034, 2019 (ESCI)

Yayın Türü: Makale / Derleme
Cilt numarası: 13 Sayı: 2
Basım Tarihi: 2019
Doi Numarası: 10.1016/j.dsx.2019.01.016
Dergi Adı: DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS
Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus
Sayfa Sayıları: ss.1031-1034
Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Introduction: Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor that improves glycemic control in patients with type II diabetes mellitus which increasing urinary glucose excretion. With numerous controlled experimental studies of dapagliflozin, evaluation of real-life data after entry into clinical practice is an important condition. In our study, the effects of dapagliflozin (10 mg) on lipid profile were investigated retrospectively.